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Abstract
Objectives: Cathepsin K, a lysosomal cysteine protease, is expressed in the tumor microenvironment (TME) of skin
carcinoma, but nothing is known about cathepsin K in oral tongue squamous cell carcinoma (OTSCC). Our aim was to
describe the expression of cathepsin K in invasive OTSCC in vitro and in a series of clinical cancer specimens.
Materials and Methods: OTSCC invasion in vitro was studied using invasive HSC-3 tongue carcinoma cells in 3D
organotypic models. In total, 121 mobile tongue OTSCCs and 10 lymph node metastases were analyzed for cathepsin K
expression. The association between cathepsin K expression and clinicopathological factors was evaluated.
Results: Cysteine protease inhibitor E64 and cathepsin K silencing significantly (p,0.0001) reduced HSC-3 cell invasion in
the 3D models. Cathepsin K was expressed in a majority of carcinoma and metastatic cells, but the expression pattern in
carcinoma cells did not correlate with clinical parameters. Instead, the weak expression of cathepsin K in the invasive TME
front correlated with increased overall recurrence (p,0.05), and in early-stage tumors this pattern predicted both cancer
recurrence and cancer-specific mortality (p,0.05 and p,0.005, respectively).
Conclusions: Cathepsin K is expressed in OTSCC tissue in both carcinoma and TME cells. Although the diminished activity
and expression in aggressive tongue HSC-3 cells reduced 3D invasion in vitro, the amount of cathepsin K in carcinoma cells
was not associated with the outcome of cancer patients. Instead, cathepsin K in the invasive TME front seems to have a
protective role in the complex progression of tongue cancer.
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Introduction
Proteases are an integral part of the maintenance of the
mesodermal connective tissue system, playing a fundamental role
in processes from early development to growth and homeostasis
[1–10]. Accordingly, alterations in the structure and expression
patterns of proteases underlie many human pathological processes
including arthritis, osteoporosis, neurodegenerative disorders,
cardiovascular diseases, and cancer [11–15]. In carcinomas,
proteolytic processing is combined with enhanced cell motility
and reduced cohesion. These allow tumor expansion where the
malignant cells protrude through the underlying basement
membrane [16]. Hence, modeling of the tumor microenvironment
has a central role in influencing tumor fate.
Cathepsin K is a lysosomal cysteine protease first characterized
in osteoclasts [17]. It has an important role in many other tissues,
as well [13,14,18,19]. In general, the expression of cathepsin K in
normal tissue seems to be associated with the process of
extracellular matrix turnover. Cathepsin K is largely absent in
skin, whereas dermal fibroblasts of surgical scars present strong
cytoplasmic cathepsin K expression [11]. This suggests that
cathepsin K is important for modeling of the dermal extracellular
matrix. Accordingly, Codriansky et al. [20] have shown that
cathepsin K is indeed a key factor in skin homeostasis, in which a
decline in cathepsin K response in UVA-damaged fibroblasts
results in an accumulation of abnormal elastin in the extracellular
space. This confirms that cathepsin K is essential to the dynamic
equilibrium between live mesenchymal cells and matrix synthesis
and degradation.
Cathepsin K has been shown to have a significant role in many
diseases, such as osteoarthritis and rheumatoid arthritis [21],
atherosclerosis [22], the progression of cerebral aneurysms [12],
and cancer progression [14]. Expression of cathepsin K has been
demonstrated in malignancies including primary prostate and
breast cancer [23,24], both of which have a high propensity to
metastasize to bone tissue. In breast cancer bone metastasis,
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inhibition of cathepsin K has dramatically reduced metastatic
lesions [25]. In cutaneous squamous cell carcinoma, cathepsin K
in stromal tissue facilitates cancer invasion [13,18]. Cathepsin K
expression has also been reported in epithelial cells of breast
tumors and melanomas [14,26].
The importance of cysteine proteinase cathepsins in the
progress of oral carcinomas is relatively unknown [27]. In oral
tissues and in oral squamous cell carcinomas (OSCCs), the
presence of cathepsin K expression has not yet been described in
the literature. Therefore, the aim of this study was to define the
role of cysteine protease cathepsin K in the invasive process of
OTSCC.
Results
Cathepsin Inhibitor E64 Reduced HSC-3 Invasion in the
Myoma Organotypic Model
In order to evaluate the effect of broad spectrum cathepsin
protease inhibitor (E64) on the invasion of aggressive tongue
carcinoma cells, HSC-3 cells were grown in a myoma organotypic
invasion assay (Figure 1). Interestingly, E64 was able to
significantly prevent HSC-3 cell invasion in the myoma as
compared with untreated cells (Figure 1A–1C) (p,0.0001). The
invasion index (the ratio between the invaded area and the total
area of AE1/AE3-stained HSC-3 cells) was also reduced, although
the difference was not statistically significant (Figure 1D)
(p=0.114). In view of these results we have chosen to concentrate
our efforts here on cathepsin K only, since it has already been
described as a potent collagenolytic enzyme that is overexpressed
in several malignancies [18,23,24,28].
Cathepsin K Knockdown Impairs HSC-3 Cell Invasiveness
in the Myoma Organotypic Model
HSC-3 cells knocked down for cathepsin K (HSC-3 shRNA
CTSK) showed a significantly reduced amount of cathepsin K
mRNA (p,0.0001) (Figure 2 C) and presented notably reduced
invasion when compared with their wild type counterparts
(Figure 2A–2B). Invasion depth (p = 0.0006), invasion area
Figure 1. Cathepsin inhibitor E64 reduces HSC-3 tongue carcinoma cell invasion in the myoma organotypic invasion model. The
effect of cathepsin inhibitor on the invasion of HSC-3 cells in the myoma organotypic assay was studied. E64 at 10 mM could prevent HSC-3 invasion
as compared with the controls (A–B). Overall HSC-3 cell invasion depth (C) as well as invasion index (the ratio between the invaded area and the total
area of AE1/AE3-stained HSC-3 cells) (D) were quantified. The invasion depth was significantly reduced (***p,0.0001), but the invasion index shows
no significant reduction (p = 0.114). Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g001
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(p,0.0001), and invasion index (p = 0.0008) were significantly
reduced in HSC-3 shRNA CTSK compared with control vector
cells grown in the myoma discs (Figure 2D–2F).
Cathepsin K is Expressed by HCS-3 and Stromal Cells in
Organotypic Models
We wanted to verify the expression of cathepsin K mRNA and
protein in tongue carcinoma HSC-3 cells cultured in two different
types of 3D organotypic models. In addition to the human-tissue-
derived myoma model used above, we tested the classic in vitro
invasion assay using rat type I collagen discs embedded with
human gingival fibroblasts [29]. Through immunohistochemistry
we could demonstrate that HSC-3 cells expressed cathepsin K in
both models (Figure 3A–3B). However, the myoma tissue, in the
absence of invading carcinoma cells, also had detectable levels of
cathepsin K immunoreactivity (Figure 3D), as did the fibroblasts
embedded in the collagen gel (Figure 3E). Western blotting
confirmed that the cultured monolayers of HSC-3 cells (Figure 3G,
lane 2), and also the myoma tissue expressed cathepsin K, as
demonstrated in two distinct myoma tissue samples (without HSC-
3 cells) (Figure 3G lanes 3 and 4). To confirm specific cathepsin K
mRNA expression by HSC-3 cells, we used laser microdissection
to isolate the invading HSC-3 cells in the myoma tissue (Figure 3F)
and by RT-PCR we revealed that the invasive HSC-3 cells
contained cathepsin K mRNA (Figure 3H), confirming the
expression of cathepsin K by oral tongue HSC-3 cells.
Immunohistological Location of Cathepsin K in OTSCC
Samples
In our 121 OTSCC patient samples, cathepsin K was detected
in the great majority of cancers (only 4 cases were negative),
including a few dysplastic areas surrounding the carcinoma tissue,
as well (Figure 4A–4C). We could not detect cathepsin K in the
morphologically normal-looking epithelium of the tongue (not
shown). In carcinomas, cathepsin K was present in both
carcinoma and stromal cells. Interestingly, the carcinoma cells
showed two kinds of staining patterns: a localized (membranous)
and a diffuse (cytoplasmic) distribution (Figure 4D–4E). The
membranous staining pattern was usually visible in the most
superficial to middle areas of the tumor, being gradually replaced
by the cytoplasmic type.
Cathepsin K Expression is Distinct in Epithelial and
Stromal Cells
In some samples, we observed a gradient of staining intensity
accompanying the variations in expression of cathepsin K. This
seems to be an epithelial-to-mesenchymal pattern shift in the
expression of cathepsin K as the tumor begins to reach more
invasive areas of the tumoral tissue. Also, even when there is no
gradient in expression from superficial to deeper areas of the
tumor, the intensity of the expression of cathepsin K by the stroma
and epithelial cells seemed to be inversely correlated, with tumor
cells presenting higher cathepsin K expression in areas where
stromal staining was weaker, and vice versa (Figure 4F–4G). The
expression of cathepsin K by TME cells was observed as abundant
diffuse staining in various inflammatory and spindle-shaped cells
(Figure 5A–5D). Staining with selective markers CD45 (for cells of
hematopoietic lineage), CD68 (for cells of the monocyte/macro-
phage lineage), and vimentin (for cells of mesenchymal origin) was
used to confirm the presence of inflammatory and mesenchymal
cells at the matching location with cathepsin K in the TME
(Figures 5F–5H). The cathepsin-K-positive cells at the stroma were
present both in the most superficial areas (Figures 5A–5B) and
surrounding the invasive front (Figures 5C–5D). Some carcinomas
contained multinucleated giant cells, which always stained
intensively for cathepsin K (Figure 5E), similar to osteoclasts of
the bone (not shown).
Figure 2. Specific cathepsin K knockdown significantly reduces HSC-3 cell invasion in the myoma organotypic invasion model. The
knockdown of cathepsin K mRNA has significantly decreased the invasion of HSC-3 shRNA CTSK cells in the myoma organotypic model when
compared with HSC-3 shRNA control cells (A–B). HSC-3 shRNA CTSK cells showed a reduction in cathepsin K mRNA levels when compared with wild
type cells and HSC-3 cells transfected with a control shRNA (scramble) *p,0.0001 (C). The invasion depth, invasion area, and invasion index were all
significantly reduced for HSC-3-shRNA CTSK cells (*p = 0.0006, **p,0.0001, and ***p = 0.0008, respectively) (D–F). Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g002
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Cathepsin K Expression Pattern is an Independent
Predictor of Disease Recurrence and Patient Mortality
We correlated our immunohistopathology analyses of cathepsin
K expression and compared them with patient clinicopathological
data. In our univariate analyses, there were no correlations
between our parameters and gender, age, grade, stage, lymph
node status, or therapy. The only correlation found was between a
gradient towards diminished expression of cathepsin K in the
TME at the invasive front and increased overall recurrence
(p,0.05). This correlation was confirmed in our survival studies
(Figure 6A). There was also a correlation between more
recurrences and cancer-specific deaths in stages 1 and 2
(Figure 6B–6C). In our multivariate analyses, we confirmed that
weaker expression of cathepsin K in the invasive TME front was
an independent predictor of overall recurrence (HR 2.594, 95%
CI [1.394–4.827]). In early-stage tongue cancers, the aforemen-
tioned cathepsin K expression pattern predicted recurrence (HR
3.093, 95% CI [1.214–7.877]) and cancer-specific mortality (HR
9.306 95% CI [2.303–37.609]).
Cathepsin K Expression Pattern is Similar in Primary
Tumors and Lymph Node OTSCC Metastases
In the ten primary cancer cases with corresponding lymph node
metastases analyzed (Figure 7A–7C), we observed that metastatic
OTSCC cells in lymph nodes were also positive for cathepsin K
(Figure 7D–7F). Not only that, the organization of the stroma
seemed to mimic the one found at the primary tumor, with
inflammatory cells organized around OTSCC cells and expressing
increased amounts of cathepsin K (Figure 7D). The vast majority
of metastasis-free lymph nodes did not express cathepsin K, with
only a very few positive randomly deposited cells (Figure 7E).
Discussion
Previously, cathepsin K expression in cancer was thought to be
limited to osteoclasts, having distinct but synergistic effects on
matrix metalloproteases (MMPs) in bone resorption associated
with tumor metastasis [17,30]. Its presence has also been
demonstrated in cutaneous SCC tumor stroma [13,14,18,19],
and it seems to be expressed to a higher degree in invasive tumors
when compared with breast and melanoma in situ carcinomas
[14,18,26]. Cathepsin K activity is complex, with roles in
Figure 3. Cathepsin K expression in the myoma organotypic model. Invasive HSC-3 cells grown on myoma show intensive cathepsin K
immunohistological staining (A). HSC-3 cells grown in type I collagen organotypic culture discs with embedded fibroblasts show cathepsin K staining
in all cells present (B). Myoma tissue (without HSC-3 cells) as well as fibroblasts embedded in the collagen gel also stained with cathepsin K antibody
(D–E). A negative control for immunostaining is shown (C). A Western blot confirmed that the monolayer cultures of HSC-3 cells (G, lane 2) and two
distinct myoma tissue samples (without added carcinoma cells) contained cathepsin K (G, lanes 3 and 4). HSC-3 cells microdissected from the
organotypic myoma model (F) of both formalin-fixed paraffin-embedded blocks (FFPE) and OCT-embedded frozen blocks (fresh frozen), as well as
HSC-3 cells cultured in vitro in monolayers, express cathepsin K mRNA, as detected by RT-PCR (H). A differentiated human osteoclast progenitor cell
line (Osteo) was used as a positive control for cathepsin K mRNA expression, represented by (+). Negative controls, where no sample was used, are
demonstrated by (2) Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g003
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angiogenesis, bone remodeling, and progenitor cell mobilization.
With these important roles in tissue homeostasis, it is interesting to
note that its expression in primary tumors, including OTSCCs,
still has not been thoroughly investigated. Much less is known
about its participation in the modulation of other molecules
necessary for local tumor invasion [18,26]. We showed here, for
the first time, that cathepsin K is abundantly expressed by
OTSCC cells in addition to the tumor microenvironment (TME),
and that its expression pattern by tumor cells has prognostic
significance.
As first demonstrated in our myoma organotypic experiments,
the invasiveness of HSC-3 cells was markedly reduced with the
introduction of cathepsin inhibitor E64, pointing to an important
role for tumor cell cathepsins. The choice of studying cathepsin K
more closely was likely to yield interesting results, since it was
already very well described in several studies that demonstrate the
power and enhanced activity of cathepsin K in the TME
[18,23,24,28]. With our specific knockdown of cathepsin K
mRNA translation, we have established that although invasion
was not completely abolished in the myoma organotypic model, it
was significantly reduced–showing that cathepsin K is a powerful
driver of HSC-3 OTSCC cell invasiveness. In our OTSCC patient
samples, cathepsin K expression in the stromal component of
OTSCCs surprisingly seems to be protective, since a poorer
prognosis for stages 1 and 2 was strongly correlated to weaker
cathepsin K expression at the invasive TME front. In this
environment, regulation of the expression of cathepsin K between
stroma and carcinoma cells appears to be far more complex and
dynamic, where cathepsin K expression intensity is complemen-
tary between stromal and epithelial cells. We postulate that
cathepsin K expression may lead to a different prognosis
depending on whether it is expressed more in the OTSCC cells
or by the cells in the surrounding stroma.
Other reports have explored in more detail the complex nature
of cathepsin K regulation and the crosstalk between the TME,
mainly carcinoma-associated fibroblasts (CAFs) [31], where
cooperation between stromal and epithelial tumor cells has
promoted the expression of cathepsin K, and enhanced tumor
invasive capacity. This highlights the importance of the TME in
the behavior of these cells, since expression intensity outside the
tumor front was not considered to be of prognostic significance. In
lymph node metastases, the pattern of cathepsin K expression was
similar to the one found in the corresponding primary tumors,
indicating that invasive tumor cells quickly mobilize the host
stromal cells and modify their new surroundings. Therefore, this
indicates that the complexity of the TME seems to be more
significant than the individual tumor elements [14,18].
In our patient samples, cathepsin K was present in OTSCC
tumor epithelial cells, but not in normal mucosa keratinocytes.
This is in line with previous findings where cathepsin K was
occasionally expressed by skin keratinocytes only in young surgical
scars, and focally in epithelial cells of the breast [14]. However, in
skin squamous cell carcinomas, epithelial expression of cathepsin
K was reported absent [13] or focal and weak compared with the
TME [26]. In our results, the TME and carcinoma cells of
OTSCC presented significant, but fluctuating expression of
Figure 4. Cathepsin K immunostaining in invasive tongue cancer tissues and dysplastic oral epithelium. Cathepsin K in OTSCC tumors
is localized in a few areas of dysplastic epithelium (dp) surrounding the cancer tissue (SCC) (A–B). A no staining area within a tumor slide with a score
of (0) is shown by the first arrow (B). Other arrows, from left to right, show weak epithelial staining (+) and moderate stromal staining (++) (B).
Cathepsin K shows a membranous, defined staining pattern in invading OTSCC carcinoma cells (C). The top arrow indicates an area with strong (+++)
epithelial diffuse staining and moderate (++) stromal staining and the arrow below indicates stromal staining at the invasive front (D). At the invasive
front, carcinoma cells show a cytoplasmic diffuse staining pattern. Big arrows indicate strong (+++) epithelial membranous staining. Empty arrows
highlight individual cells in the stroma with moderate staining (++) (E). Arrows indicate different intensities of cathepsin K staining in superficial and
invasive areas of tumor from weak (+) to moderate (++), illustrating the expression gradient observed in the samples (F). Example of strong stromal
staining (full arrows) (+++) when epithelial staining is only moderate or weak (empty arrows) (G). Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g004
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cathepsin K. We believe that our high number of cases and our
focus on only OTSCC will give a better understanding of how the
molecular differences between tumors of different locations might
explain their often different clinical outcomes.
The reasons for the variable expression of cathepsin K in the
invasive carcinoma cells and tumor front of the TME and its
seemingly complementary relationship in vitro can obviously be
due to the more complex regulation and interaction of cells in
cancer. There are some reports in the literature that discuss
cathepsin K in tumors [13,14,18,23,24,26], but none on OTSCCs
and their microenvironments. We can readily postulate two
explanations for the observed inverse relationship between patient
survival and cathepsin K expression in OTSCC stroma. One
explanation is that lower cathepsin K expression leads to a
diminished reduction in growth factor activity, which is already
shown to be a plausible phenomenon during airway development,
where TGF-b1 levels are affected [32]. Alternatively, we can
presume that more enhanced cathepsin K activity exists in sites
where it is needed to complement the absence of other enzymes.
As the enzymatic activity grows in the stroma, there might be a
feedback mechanism of active cathepsin K repression, such as
activation of cystatins. In another approach, several enzymes
overexpressed at the tumoral front, through some unspecific
activity, might be miscleaving the pro-cathepsin K present in these
tissues, therefore effectively halting their maturation process [33].
In vivo, the situation is far more complex, and the role of growth
factors and feedback mechanisms can be more determinant in the
final prognosis, which is strongly influenced by metastasis and
growth capacity of the tumor.
Due to its potential role in osteoporosis, cathepsin K is currently
one of the cysteine proteinases most intensively investigated by the
pharmaceutical industry [34]. Inhibitors of cathepsin K have
shown promising results in clinical trials for postmenopausal
osteoporosis, indicating that these drugs may soon become
commercially widely available [34,35,36]. However, since the
function of cathepsin K is not yet fully clarified in OTSCC, and
especially in the TME, our results suggest that we should be aware
of the possible effects of cathepsin K inhibitor treatment on
changes in the protective/destructive balance of cathepsin K
expression in oral tongue tumors.
In conclusion, these results support the idea that oral carcinoma
cells can use multiple mechanisms as they infiltrate into adjacent
tissues, bringing another level of complexity to the TME. Based on
this, cysteine proteases, such as cathepsin K, seem to be important
regulators of OTSCC invasion. As our knowledge of cathepsin K
participation in the development of tumors is expanding, there is
also interest in evaluating its contribution to development and
invasion in OTSCC, providing more tools for understanding,
predicting, and developing better therapeutic alternatives for
stemming OTSCC progression.
Materials and Methods
Ethics Statement
Patients signed an informed consent form and data inquiry was
approved by the National Supervisory Authority for Welfare and
Health (VALVIRA), # 6865/05.01.00.06/2010 (5.10.2010), and
the Ethics Committee of the Northern Ostrobothnia Hospital
Figure 5. Cathepsin K is expressed by various stromal cells. Adjacent stroma of some OTSCC tumors shows strong staining for cathepsin K
(A–B). Arrows show several round nuclear inflammatory and spindle mesenchymal cells in OTSCC stroma that have abundant cathepsin K staining (C–
D). In matching areas of the TME, where cathepsin K was expressed, we also observed cells positive for the selective immunohistochemical markers
CD45 (F), CD68 (G), and vimentin (H), confirming the presence of inflammatory and mesenchymal cells. Arrows indicate positive cells and dotted lines
indicate OTSCC cell islands (F–H). Multinucleated giant tumor cells are intensively stained for cathepsin K (E). Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g005
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District, statement 49/2010 (16.8.2010). Use of patient material
for this study was approved by the Northern Ostrobothnia
Hospital District Ethics Committee (statement #8/2006 and
amendment 19/10/2006).
Cell Culture
Human HSC-3 tongue carcinoma cells (JCRB Cell Bank 0623,
National Institute of Health Sciences, were cultured in 1:1 of
DMEM and Ham’s F12 culture medium supplemented with 10%
foetal bovine serum, 100 U/ml penicillin, streptomycin (100 mg/
mL), 250 ng/mL Fungizone (Invitrogen, USA), 50 mg/mL
ascorbic acid, and 0.4 ng/ml hydrocortisone, as described in
detail earlier [37]. The gingival fibroblasts were cultured as
described before [29].
Osteoclast Progenitor Cells and Differentiation
Isolation of osteoclast progenitor cells from human bone
marrow and human osteoclast differentiation were carried out as
described before in [38]. Briefly, non-adherent mesenchymal
progenitor cells were collected and the monocyte fraction was
purified. Cells were plated on ultrasonicated human cortical bone
slices for seven days; half of the culture medium was replaced twice
a week with fresh medium (demi-depletion). After seven days, the
pH of the culture medium was lowered to 6.8 with sterile 0.5 M
HCl and culturing was continued for an additional three days,
after which the cells were lysed for RNA isolation.
Cathepsin K shRNA Transduced Cells
Target cells were plated in a 12-well plate to 50% confluence 24
hours prior to viral infection with 1 ml of complete medium.
CTSK shRNA and control shRNA lentiviral particles (reference
numbers sc-29936-V and sc-108080) were purchased from Santa
Cruz Biotechnology (USA). We prepared fresh medium with
5 mg/ml of PolybreneTM and added 1 ml of this medium to
cathepsin K shRNA and control shRNA lentiviral particles and
incubated them overnight. We then split cells in a 1:5 concentra-
tion and continued incubation for 48 hours in complete medium.
Selection was achieved with Puromycin dihydrochloride (Sigma-
Figure 6. Weaker staining of cathepsin K in the invasive front correlates with shorter recurrence-free survival and increased
mortality. Survival analyses show a shorter overall recurrence-free interval in patients with a lower cathepsin K staining gradient (cat-K gradient 2)
compared with those with either higher (cat-K gradient +) or no gradient (gradient 0) of cathepsin K staining intensities in the invasive front
compared with the upper part of the tumor (A), especially seen in patients with stage 1 or 2 OTSCC (B). Disease-specific survival of patients with
stages 1 and 2 OTSCC tumors was better in patients with a positive or no gradient of cathepsin K staining compared with those with a negative
gradient (C).
doi:10.1371/journal.pone.0070925.g006
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Aldrich, USA). Resistant colonies were expanded for detection of
stable shRNA expression through real-time PCR (qPCR).
Collagen Gel Organotypic Culture
The 3D collagen gel experiment was done as described
previously by Nurmenniemi et al. [29]. Briefly, 8 volumes of rat-
tail-derived type I collagen (3.45 mg/ml; BD Biosciences, Bedford,
MA), 1 volume of 106DMEM (Sigma-Aldrich), and 1 volume of
fetal bovine serum with gingival fibroblasts (final concentration in
gel 76105 cells/ml) were mixed on ice and allowed to polymerize
on 24-well plates at 37uC for 30 minutes. After polymerization,
76105 cancer cells were added on each gel. The next day the gels
were detached from the well walls, allowed to contract for 4 hours,
and lifted onto collagen-coated (BD Biosciences) nylon disks
(Prinsal Oy, Finland) resting on curved steel grids (3621621 mm).
The grids were placed on 6-well plates, and a sufficient volume of
culture medium (2.5 ml) was added to reach the undersurface of
the grid, generating an air-liquid interface. This was day 1 of the
culture. The media of the organotypic cultures were changed
every 3 days for 14 days, whereupon the cultured tissues were
harvested.
Human Myoma Organotypic Culture and Quantification
of Invasion Results
The myoma organotypic experiment was done as described
previously [29], with the following changes. Ten days prior to the
experiment the myoma disks were equilibrated at +4uC in cell
culture medium, which was changed regularly. The myoma disks
were pre-incubated 12 h prior to the experiment in a culture
medium containing cathepsin inhibitor E64 (Sigma-Aldrich) at a
concentration of 10 mM and the HSC-3 cells for 1 hour at 37uC in
a humidified 5% CO2 atmosphere. Then the myoma disks (3 per
group) were placed into Transwell inserts and 76105 cells per
myoma were added and allowed to attach overnight in media
containing E64 (10 mM). Next, the myoma disks were moved to
uncoated nylon disks on curved steel grids in 12-well plates with
1 ml of medium containing 10 mM E64. During the experiment,
the medium with the inhibitor was changed every third day. The
myoma cultures were maintained for 10 days and then the disks
were fixed in 4% neutral-buffered formalin overnight. The myoma
disks were bisected and either embedded in OCT compound and
frozen at 270uC until use or dehydrated and embedded in
paraffin. Paraffin blocks were cut into 5-mm sections and tissue
sections were stained with primary antibody against pancytoker-
atin, clones AE1/AE3, at a 1:250 dilution (Dako, Copenhagen,
Denmark) to detect carcinoma cells of epithelial origin from the
HSC-3 myoma tissue sections, and the depth of invasion and
invasion index of the HSC-3 cells were quantified as described
previously [29,39].
Patient Samples and Clinicopathological Data
Archival specimens of 121 OTSCC samples, surgically treated
at the Oulu University Hospital in 1981–2009, were retrieved
from the Oulu University Hospital, Department of Pathology. The
median age of the patients was 65 years (range 27–99). The
median follow-up time was 121 months (range 24–298 months) in
the surviving patients (n = 54). The median follow-up time for the
study patients was 53 months (range 1–298 months). Patient
survival data were acquired from Statistics Finland and other
relevant data from patient records (Table 1). We could not retrieve
treatment data from three of the patients or survival data from two
of the patients. We also used ten samples of lymph nodes with
metastatic OTSCC lesions, which were analyzed only for their
immunohistopathological features.
Figure 7. Cathepsin K immunostaining pattern in lymph node metastases of OTSCC is similar to the primary tumor. Metastatic
carcinoma cells were identified with pancytokeratin staining (A–B), followed by cathepsin K staining of the paired primary OTSCC (C) and lymph node
metastases (D) (n = 10, the paired sections were taken from the same patient). The arrows indicate similar cathepsin K staining patterns in both the
primary tumor and in the lymph node metastases. Lymph nodes without metastases contain some cathepsin K positive cells (E), but the stromal
reaction drastically changes in the presence of cathepsin K positive OTSCC cells (F). Scale bars 200 mm.
doi:10.1371/journal.pone.0070925.g007
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Immunohistochemistry
For HSC-3 cells in the myoma and collagen discs as well as the
OTSCC and lymph node samples, cathepsin K immunostainings
were performed on paraffin-embedded sections. Specimens of
OTSCC were previously selected to be representative of the tumor
mass in the resected specimens. The slides were deparaffinized,
rehydrated, and washed with 0.3% hydrogen peroxide to inhibit
endogenous peroxidase. After a high-temperature antigen retrieval
procedure in Tris-EDTA buffer for 15 minutes, the slides were
washed with PBS and incubated with cathepsin K primary
antibody (Biovendor, USA), clone: 3F9 for 1 h at room
temperature at a 1:500 dilution. For OTSCC clinical samples
we also employed selective markers for cells of monocyte/
macrophage lineage (CD68, clone: PG-M1 at a 1:10000 dilution,
Dako), cells of hematopoietic lineage (CD45, clone: A20 at a 1:400
dilution, BioLegend, USA), and cells of mesenchymal origin
(vimentin, clone: V9 at a 1:1500 dilution, Dako), also for 1 h at
room temperature. For lymph nodes, also primary antibody
against pancytokeratin, to detect metastatic carcinoma cells
(clones: AE1/AE3, at a 1:250 dilution, Dako), was used. To
detect antibody reactions, we used a Dako Envision kit (Dako) with
Diaminiobenzidine (Dako basic DAB-kit) as a chromogen.
Counterstaining was done in a Dako Autostainer (Dako).
Validation of our immunohistochemical analysis was done using
positive controls (human bone tissue) and two series of negative
controls (by omitting the primary antibody and by replacing the
primary antibody with mouse primary antibody isotype control).
Western Blot
Total protein from cultured HSC-3 and myoma tissue samples
(without invading HSC-3 cells) was extracted by homogenizing the
cells and tissue in a lysis buffer (50 mM Tris, 10 mM CaCl2,
150 mM NaCl, 0.05% Brij, pH 7.5) on ice, rotating them at 4uC
for 4 h and collecting the supernatant by centrifugation at
120006g for 10 min. Western blot analysis using polyclonal
cathepsin K in a 1:50 dilution (Abcam, Cambridge, UK) was done
as described previously [40].
Laser Capture Microdissection
Myoma tissue samples (with invading HSC-3 cells) were fixed in
buffered formalin and embedded in paraffin, or snap-frozen in
OCT compound (Sakura, USA). Sections were cut and mounted
on polyethylene naphthalate (PEN) membrane-coated slides
(P.A.L.M. Microlaser Technologies, Germany). Areas of invading
HSC-3 cells were cut and collected by pressure catapulting from
the myoma tissue by means of laser microdissection using the
P.A.L.M. Robot-microlaser system (P.A.L.M. Microlaser Tech-
nologies) according to the manufacturer’s instructions.
Cathepsin K RT-PCR and qPCR
RNA from HSC-3 cells, HSC-3 shRNA CTSK, and shRNA
control, as well as from differentiated human osteoclast progenitor
cells and microdissected samples was isolated with TRIzol reagent
(Invitrogen) or with an RNeasy FFPE kit (QIAGEN, USA)
according to the manufacturer’s protocol. For the first strand
cDNA synthesis, 1 mg of total RNA per sample was used and the
reaction was performed with a superscript enzyme (RevertAidTM
Reverse Transcriptase enzyme, Fermentas-Thermo Scientific,
USA). We used cathepsin K primers (forward 59-ccgcagtaatga-
cacccttt-39 and reverse 59-gcacccacagagctaaaagc-39) and beta-
actin (forward 59-aactgggacgacatggagaaaa-39 and reverse 59-ag
aggcgtacagggatagcaca-39) as a reference gene. Briefly, PCR
reactions were done in 45 cycles of 5 minutes at 95uC, 2 minutes
at 94uC, 1 minute at 54uC, 30 seconds at 72uC, and a final
extension at 72uC for 10 minutes, using DNA polymerase
AmpliTaqGoldTM (Fermentas). The PCR products were then
analyzed in a 1% agarose gel and stained with ethidium bromide.
The size of the amplification products was confirmed with a
100 bp ladder commercial molecular weight marker (Fermentas).
For qRT-PCR we used the StepOnePlus Real Time PCR System
(Applied Biosystems Inc., USA). Each experiment was done with
12.5 ml of SYBRH Green PCR Master Mix (Applied Biosystems
Inc., USA), 2 ml of 10 nM of each primer, and 1 ml of sample. b-
actin was used as the internal control. All the experiments were
repeated three times.
Immunohistochemical Assessment of Cathepsin K
Expression
Cathepsin K immunostaining was analyzed by three indepen-
dent researchers (C.C.B., J.H.K., and T.S.) who had no previous
knowledge of the clinical data. Expression of cathepsin K was
evaluated using an intensity-of-labeling scale (no staining= 0, weak
staining =+, moderate staining= ++ and strong staining= +++) in
overall tumor epithelial and overall as well as invasive stromal
staining. The process of scoring the intensity of staining was
completed first by calibrating the researchers with cases of clear
Table 1. Data retrieved from the files of patients whose
samples were used in this study.
Patient clinical data
N %
Age at diagnosis
,55 yrs 40 33.0
55–70 yrs 33 27.3
.70 yrs 48 39.7
Sex
Male 60 49.6
Female 61 50.4
Tumor grade
1 44 36.4
2 62 51.2
3 15 12.4
Tumor stage
1–2 64 52.9
3–4 57 47.1
Neck lymph nodes
Negative 81 66.9
Positive 40 33.1
Recurrence
No 80 66.9
Yes 41 33.1
Adjuvant therapy
No 69 57.0
Radiotherapy 38 31.4
Radio- and chemotherapy 11 9.1
Missing 3 2.5
Total 121
doi:10.1371/journal.pone.0070925.t001
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examples of each of the above-mentioned classification tiers
(examples in Figure 4). After consensus, the analysis of each slide
started with a no staining area with a score of (0). Following that,
we analyzed the following criteria in the same order: overall
stroma staining intensity (0 to +++), overall epithelial staining
intensity (0 to +++), and overall invasive stroma staining (0 to +++).
In all cases we selected 3 different areas for each parameter and
only considered scoring if consensus was reached. Other
parameters considered were the pattern of cathepsin K expression
in superficial and invasive front tumor epithelia (membranous or
diffuse staining) and cathepsin K expression in an invasive front
compared with superficial tumor stroma (more, less, and no
difference) (Figures 4 and 5).
Statistical Analysis
Differences in tumor metastasis, size, and sample staining
between groups were compared with the Mann-Whitney or
Student’s T-test. To estimate statistical significance in the myoma
samples, an independent sample T-test was performed. Results
with p,0.05 were considered statistically significant. In vitro
invasion data are expressed as box blots. The line across the box
indicates the median; the box contains the values between the 25th
and 75th percentiles, and the whiskers show the highest and lowest
values. We used PASW Statistics 18 (IBM corp.) software for
statistical analyses of the patient material. A chi-square test was
used to calculate statistically significant differences between
prognostic and clinicopathological variables. Survival tables were
calculated according to the Kaplan-Meier method, and were
compared with the log-rank test. Multivariate survival and
recurrence analyses were done with the Cox proportional hazards
model using the following covariates: gender (male or female), age
at the time of diagnosis (,55 yrs, 55–70 yrs, and .70 yrs), tumor
stage (1–2 and 3–4) and tumor histologic grade (1, 2, and 3). For
stage 1–2 tumors, only gender, age, and grade were used. Cox
regression was done using backward stepwise selection of variables,
and a p value of 0.05 was adopted as the limit for inclusion of a
covariate. The backward stepwise algorithm was used to pick the
best combination of prognostic factors to explain mortality or
recurrence in the study population. The hazard ratios and 95%
confidence intervals are provided for each covariate.
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